959163-01-0

Basic information

• Product Name: 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde
• Synonyms: 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde;6-chloro-4-(ethylamino)nicotinaldehyde
• CAS NO: 959163-01-0
• Molecular Formula: C₈H₉ClN₂O
• Molecular Weight: 184.62286
• Mol File: 959163-01-0.mol

Chemical Properties

• Boiling Point: 347.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.297±0.06 g/cm3(Predicted)
• PKA: 1.09±0.10(Predicted)
• CAS DataBase Reference: 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde(959163-01-0)
• EPA Substance Registry System: 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde(959163-01-0)

Safety Data

• Hazardous Substances Data: 959163-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and pharmaceutical compounds. Its structural properties make it a valuable precursor in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical industry, 6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde is utilized as a building block, playing a crucial role in the creation of compounds that are used to protect crops from pests and diseases, thereby ensuring agricultural productivity.
Used in Dye Manufacturing:
6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde is also employed in the production of dyes, where its chemical properties contribute to the development of colorants used in various applications, including textiles, plastics, and printing inks.
Used in the Production of Fine Chemicals:
6-chloro-4-(ethylamino)-3-Pyridinecarboxaldehyde is used as a key component in the synthesis of fine chemicals, which are high-purity chemicals used in various specialized applications, such as in the fragrance, flavor, and chemical research industries.

Upstream product

• 959162-97-1 6-chloro-4-ethylamino-nicotinic acid ethyl ester 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 959162-99-3 (6-chloro-4-(ethylamino)pyridin-3-yl)methanol 

Downstream Products

• 1012878-78-2 3-(3-amino-4-fluorophenyl)-7-chloro-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-69-0 3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(2-methoxyethylamino)-1,6-naphthyridin-2(1H)-one 
• 1442470-70-3 3-(5-amino-2-chloro-4-fluorophenyl)-1-ethyl-7-(tetrahydrofuran-3-ylamino)-1,6-naphthyridin-2(1H)-one 
• 1442470-71-4 3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(2-(methylthio)ethylamino)-1,6-naphthyridin-2(1H)-one 
• 1442470-72-5 7-(4-methoxybenzylamino)-3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-73-6 7-amino-3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-74-7 7-(4-methoxybenzylamino)-3-(5-amino-4-fluoro-2-methylphenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1012878-90-8 7-amino-3-(5-amino-4-fluoro-2-methylphenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-75-8 7-amino-3-(5-amino-2-chloro-4-fluorophenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-76-9 7-(4-methoxybenzylamino)-3-(5-amino-2,4-difluorophenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-43-0 7-((4-methoxybenzyl)(methyl)amino)-3-(5-amino-2-chloro-4-fluorophenyl)-1-ethyl-1,6-naphthyridin-2(1H)-one 
• 1442470-93-0 prop-1-en-2-yl (4-chloro-5-(1-ethyl-7-((4-methoxybenzyl)(methyl)amino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)carbamate 
• 1442470-98-5 prop-1-en-2-yl (4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)carbamate 
• 1442471-00-2 prop-1-en-2-yl (3-(2-chloro-4-fluoro-5-(3-phenylureido)phenyl)-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)carbamate 

Relevant articles and documents

GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS

The present invention relates to certain gem-disubstituted heterocyclic compounds, which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutat

FGFR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A compound having a structure of formula (I) and a preparation method therefor, and a use of the compound serving as an FGFR inhibitor for treating tumors, cancers, myeloproliferative diseases, bone or chondrocyte disorders, and hypophosphatemia.

HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS

The present invention relates to certain substituted heterocondensed pyridone analogues of formula (I) which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutat

Inhibitors of the fibroblast growth factor receptor

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS

Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that